ClinicalTrials.gg
CompletedNCT01491737PERTAINUpdated Oct 28, 2020Results posted

A Study of Pertuzumab in Combination With Trastuzumab Plus an Aromatase Inhibitor in Participants With Metastatic Human Epidermal Growth Factor Receptor 2 (HER2)-Positive and Hormone Receptor-Positive Advanced Breast Cancer

A Phase 2 interventional study of Pertuzumab and Trastuzumab in Breast Cancer, sponsored by Hoffmann-La Roche. Completed at 82 sites in 8 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-10-28.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
258
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 104 studies testing pertuzumab in Breast Neoplasms — 26 open to participants now, 45 under way, 7 of them phase 3. pertuzumab · Breast Neoplasms.

Enrollment
28th of 104
258 · median 100
Started
2012
with 2 others
Phase 2
59 of 104
17 open now
Registered
12th of 104
by date
Lead sponsor
20 of 104
Hoffmann-La Roche

Among the 104 studies testing pertuzumab in Breast Neoplasms, this one is the 28th largest by enrollment, is one of 3 that started in 2012, is one of 59 in phase 2, and was the 12th registered.

Breast Neoplasms

14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

26 of the 104 studies testing pertuzumab in Breast Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

21 more — sign in →

By country, each count listing its studies:

All 26 open studies →

About pertuzumab

pertuzumab: first FDA approval 2012 (PERJETA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 104 studies testing pertuzumab in Breast Neoplasms, or all of them as a file.
02

Study summary

This randomized, open-label, two-arm, multi-center, Phase II study will evaluate the efficacy and safety of pertuzumab in combination with trastuzumab plus an aromatase inhibitor (AI) in first-line participants with HER2-positive and hormone receptor-positive advanced breast cancer. Participants will be randomized to one of two treatment arms; Arm A (pertuzumab in combination with trastuzumab plus an AI) or Arm B (trastuzumab plus an AI). Participants may also receive induction chemotherapy (a taxane, either docetaxel or paclitaxel) at the investigator's discretion in combination with the assigned treatment arm. The anticipated time on study treatment is until disease progression, unacceptable toxicity, withdrawal of consent, or death whichever occurs first.

03

Conditions studied

  • Breast Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants with -positive and hormone receptor-positive advanced or locally advanced breast cancer
  • status over 1 year
  • HER2-positive as assessed by local laboratory on primary or metastatic tumor
  • Hormone-receptor positive defined as estrogen receptor-positive and/or progesterone receptor-positive
  • At least one and/or non-measurable disease evaluable according to Version 1.1

Exclusion criteria

Exclusion Criteria:

  • Previous systemic non-hormonal anticancer therapy in the or locally advanced breast cancer setting
  • Previous treatment with anti- agents for breast cancer, except trastuzumab and/or lapatinib in the or adjuvant setting
  • Disease progression while receiving adjuvant trastuzumab and/or lapatinib treatment
  • History of persistent Grade 2 or higher hematological toxicity according to National Cancer Institute-Common Toxicity Criteria Version 4.0
  • Disease-free interval from completion of adjuvant/neo-adjuvant systemic non-hormonal treatment to recurrence of within 6 months
  • Other within the last 5 years, except for carcinoma in situ of the cervix or basal cell carcinoma
  • Clinical or radiographic evidence of central nervous system metastases or significant cardiovascular disease
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HER2

HER2 is a protein, made from the ERBB2 gene, that drives the growth of some cancers. A study may look for a level of the protein, extra copies of the gene, or a particular change in it.

In breast cancer, protein tests are read as HER2-positive, HER2-low or HER2-negative; other cancers use their own rules. Check which test result the study requires.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
258 participants (actual)

Study arms

  • Experimental
    Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy

    Participants will receive pertuzumab in combination with trastuzumab plus aromatase inhibitor (AI) until pre-defined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first. Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion.

    Drug: Pertuzumab · Drug: Trastuzumab · Drug: Aromatase Inhibitor · Drug: Induction Chemotherapy

  • Active comparator
    Arm B: Trastuzumab + AI +/- Chemotherapy

    Participants will receive trastuzumab plus aromatase inhibitor (AI) until predefined study end, disease progression, unacceptable toxicity, withdrawal of consent or death, whichever occurs first. Participants may also receive induction chemotherapy (docetaxel every 3 weeks or paclitaxel weekly) up to the first 18-24 weeks of the treatment period at the investigator's discretion.

    Drug: Trastuzumab · Drug: Aromatase Inhibitor · Drug: Induction Chemotherapy

Interventions

  • Participants will receive a loading dose of 840 milligrams (mg) as an intravenous infusion on Day 1 of first treatment cycle, followed by 420 mg on Day 1 or Day 2 of each subsequent 3-week cycle until disease progression or unacceptable toxicity.

    Also known as: Perjeta®, rhuMAb 2C4

  • Participants will receive a loading dose of 8 milligrams per kilogram (mg/kg) as an intravenous infusion on Day 1 or 2 of first treatment cycle, followed by 6 mg/kg on Day 1 or Day 2 of each subsequent treatment 3-week cycles until disease progression or unacceptable toxicity.

    Also known as: Herceptin®, rhuMAb HER2

  • Participants will receive 1 mg anastrozole or 2.5 mg letrozole orally once daily.

  • DrugInduction Chemotherapy

    Participants receiving induction chemotherapy up to the first 18-24 weeks of the treatment period will receive a taxane (docetaxel every 3 weeks or paclitaxel weekly), administered in line with the respective pertuzumab and/or trastuzumab infusions at the investigator's discretion.

This study also gives Anastrozole. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Progression-Free Survival (PFS)

    Progression-free survival (PFS) was defined as the time from randomization until the first radiographically documented progression of disease or death from any cause, whichever occurred first (either during study treatment or during follow-up). Progression of disease was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 and is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum of target lesion diameters must also demonstrate an absolute increase of at least 5 mm (Note: the appearance of one or more new lesions is also considered progression). Participants with no PFS events were censored at the time of the last evaluable tumor assessment. The primary analysis of PFS was planned to be performed when a total of 165 PFS events had occurred, and the final analysis after at least 60 months follow-up.

    Time frame: Median [full range] of follow-up time on study for: Primary Analysis: 31.7 [0.0-44.3] months vs. 30.4 [0.0-45.8] months in Arm A vs. Arm B; Final Analysis: 73.20 [0.03-88.34] months vs. 71.06 [0.03-88.97] months in Arm A vs. Arm B

Secondary outcomes

  1. Overall Survival (OS)

    Overall survival (OS) was defined as the time from the date of randomization to the date of death, regardless of the cause of death. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication (pertuzumab, trastuzumab, AI or induction chemotherapy), and participants with no post-baseline information were censored at the date of randomization. The primary analysis of OS was planned to be performed at the same time as for PFS (when a total of 165 PFS events had occurred), and the final analysis was planned after at least 60 months follow-up for all participants.

    Time frame: Median [full range] of follow-up time on study for: Primary Analysis: 31.7 [0.0-44.3] months vs. 30.4 [0.0-45.8] months in Arm A vs. Arm B; Final Analysis: 73.20 [0.03-88.34] months vs. 71.06 [0.03-88.97] months in Arm A vs. Arm B

  2. Overall Response Rate (ORR)

    The overall response rate (ORR) was defined as the percentage of participants with best (confirmed) overall response (BOR) of either complete response (CR) or partial response (PR) from start of study treatment until progressive disease (PD)/recurrence or death, as assessed by the investigator according to RECIST version 1.1. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference baseline sum diameters; stable disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Participants needed to have two consecutive assessments of PR or CR at least 4 weeks apart to be a responder. Analysis of this outcome measure was only planned to occur at the time of primary analysis.

    Time frame: Median [full range] of follow-up time on study for Primary Analysis: 31.7 [0.0-44.3] months vs. 30.4 [0.0-45.8] months in Arm A vs. Arm B

  3. Clinical Benefit Rate (CBR)

    Clinical Benefit Rate (CBR) was defined as the percentage of participants with best (confirmed) partial response (PR) or complete response (CR) or stable disease (SD) for at least 6 months. According to RECIST version 1.1, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Analysis of this outcome measure was only planned to occur at the time of primary analysis.

    Time frame: Median [full range] of follow-up time on study for Primary Analysis: 31.7 [0.0-44.3] months vs. 30.4 [0.0-45.8] months in Arm A vs. Arm B

  4. Duration of Response (DOR)

    Duration of response (DOR) was defined as the period from the date of initial confirmed partial response (PR) or complete response (CR) until the date of progressive disease or death from any cause. According to RECIST version 1.1, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants with no documented progression after CR or PR were censored at the last date at which they were known to have had the CR or PR, respectively. The primary analysis of DOR was planned to be performed at the same time as for PFS (when a total of 165 PFS events had occurred), and the final analysis was planned after at least 60 months follow-up for all participants.

    Time frame: Median [full range] of follow-up time on study for: Primary Analysis: 31.7 [0.0-44.3] months vs. 30.4 [0.0-45.8] months in Arm A vs. Arm B; Final Analysis: 73.20 [0.03-88.34] months vs. 71.06 [0.03-88.97] months in Arm A vs. Arm B

  5. Time to Response (TTR)

    Time to Response (TTR) was defined as the time from the date of randomization to the date of first complete response (CR) or partial response (PR). According to RECIST version 1.1, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For participants who did not have a confirmed response, a censored TTR was calculated at the date of the last adequate tumor assessment. If no tumor assessment is performed for the participant (or all post-baseline assessments are not evaluable or PD) the censoring day would be set to day 1 (date of randomization). Analysis of this outcome measure was only planned to occur at the time of primary analysis.

    Time frame: Median [full range] of follow-up time on study for Primary Analysis: 31.7 [0.0-44.3] months vs. 30.4 [0.0-45.8] months in Arm A vs. Arm B

  6. Change From Baseline in Health-Related Quality of Life as Determined by European Quality of Life 5-Dimension (EQ-5D) Visual Analog Scale (VAS) Scores

    The EQ-5D VAS is a participant-rated questionnaire to assess health-related quality of life (QoL) in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

    Time frame: Baseline and every 3 cycles until treatment discontinuation (up to Cycle 120; 1 cycle is 21 days)

  7. Overview of the Number of Participants With Adverse Events, Severity Determined According to NCI-CTCAE Version 4.03

    All adverse events (AEs) occurring during the study and until the post-treatment safety follow-up visit approximately 28 days after last study medication were recorded; thereafter, only study drug-related serious adverse events (SAEs) continued to be collected. The investigator graded all AEs for severity per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. AEs suggestive of congestive heart failure (CHF) were identified by the SMQ (wide) "Cardiac Failure" with a status of "serious", which included the preferred terms cardiac failure, left ventricular dysfunction, and pulmonary oedema.

    Time frame: From Baseline until the end of post-treatment follow-up (up to 89 months)

  8. Number of Participants Who Died Over the Course of the Study by Reported Cause of Death and Time of Death Relative to First or Last Dose of Study Treatment

    The causes of death over the course of the study, regardless of whether the death was related to study treatment, are listed by preferred term according to the Medical Dictionary for Regulatory Activities (MedDRA), version 22.1.

    Time frame: From Baseline until the end of post-treatment follow-up (up to 89 months)

  9. Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Values Over the Course of the Study

    Left ventricular ejection fraction (LVEF) is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram or multiple-gated acquisition (MUGA) scan. All participants must have had a baseline LVEF of at least (≥)50% to enroll in the study; patients with clinically significant cardiovascular disease or baseline LVEF below 50% were not eligible for this study.

    Time frame: Baseline and every 3 cycles until treatment discontinuation (up to Cycle 120; 1 cycle is 21 days)

07

Results

Posted Jun 7, 2017

Participant flow

Participant flow — Overall Study
MilestoneArm A: Pertuzumab + Trastuzumab + AI +/- ChemotherapyArm B: Trastuzumab + AI +/- Chemotherapy
Started129129
Received at least one dose of study drug127124
Entered follow-up (post-treatment)120116
Completed00
Not completed129129
Withdrew: Withdrawal by subject2017
Withdrew: Lost to follow-up210
Withdrew: Death6357
Withdrew: Study termination by sponsor3636
Withdrew: Reason not specified89

Outcome measures

PrimaryProgression-Free Survival (PFS)

Progression-free survival (PFS) was defined as the time from randomization until the first radiographically documented progression of disease or death from any cause, whichever occurred first (either during study treatment or during follow-up). Progression of disease was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST), version 1.1 and is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). The sum of target lesion diameters must also demonstrate an absolute increase of at least 5 mm (Note: the appearance of one or more new lesions is also considered progression). Participants with no PFS events were censored at the time of the last evaluable tumor assessment. The primary analysis of PFS was planned to be performed when a total of 165 PFS events had occurred, and the final analysis after at least 60 months follow-up.

Time frame:
Median [full range] of follow-up time on study for: Primary Analysis: 31.7 [0.0-44.3] months vs. 30.4 [0.0-45.8] months in Arm A vs. Arm B; Final Analysis: 73.20 [0.03-88.34] months vs. 71.06 [0.03-88.97] months in Arm A vs. Arm B
Reported as:
Median · months
Progression-Free Survival (PFS)
monthsArm A: Pertuzumab + Trastuzumab + AI +/- ChemotherapyArm B: Trastuzumab + AI +/- Chemotherapy
Primary Analysis18.89 (14.09 to 27.66)15.80 (11.04 to 18.56)
Final Analysis20.63 (14.39 to 28.35)15.80 (11.04 to 18.66)
Statistical analysis
  • Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy vs Arm B: Trastuzumab + AI +/- Chemotherapy · Log Rank · p = 0.0070 (Test was performed at 2-sided alpha of 5%.) · Hazard ratio (hr): 0.65 · 95% CI 0.48 to 0.89Hazard ratio comparing Arm A vs. B from stratified Cox proportional hazards model including stratification factors.
  • Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy vs Arm B: Trastuzumab + AI +/- Chemotherapy · Log Rank · p = 0.0059 · Hazard ratio (hr): 0.67 · 95% CI 0.50 to 0.89Hazard ratio comparing Arm A vs. B from stratified Cox proportional hazards model including stratification factors.
SecondaryOverall Survival (OS)

Overall survival (OS) was defined as the time from the date of randomization to the date of death, regardless of the cause of death. Participants who were alive at the time of the analysis were censored at the date of the last follow-up assessment. Participants without follow-up assessment were censored at the day of last study medication (pertuzumab, trastuzumab, AI or induction chemotherapy), and participants with no post-baseline information were censored at the date of randomization. The primary analysis of OS was planned to be performed at the same time as for PFS (when a total of 165 PFS events had occurred), and the final analysis was planned after at least 60 months follow-up for all participants.

Time frame:
Median [full range] of follow-up time on study for: Primary Analysis: 31.7 [0.0-44.3] months vs. 30.4 [0.0-45.8] months in Arm A vs. Arm B; Final Analysis: 73.20 [0.03-88.34] months vs. 71.06 [0.03-88.97] months in Arm A vs. Arm B
Reported as:
Median · Months
Overall Survival (OS)
MonthsArm A: Pertuzumab + Trastuzumab + AI +/- ChemotherapyArm B: Trastuzumab + AI +/- Chemotherapy
Primary AnalysisNA (NA to NA)NA (41.40 to NA)
Final Analysis60.16 (47.21 to 79.01)57.17 (45.44 to NA)
Statistical analysis
  • Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy vs Arm B: Trastuzumab + AI +/- Chemotherapy · Log Rank · p = 0.5850 · Hazard ratio (hr): 1.15 · 95% CI 0.69 to 1.91Hazard ratio comparing Arm A vs. B from stratified Cox proportional hazards model including stratification factors.
  • Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy vs Arm B: Trastuzumab + AI +/- Chemotherapy · Log Rank · p = 0.7833 · Hazard ratio (hr): 1.05 · 95% CI 0.73 to 1.52Hazard ratio comparing Arm A vs. B from stratified Cox proportional hazards model including stratification factors.
SecondaryOverall Response Rate (ORR)

The overall response rate (ORR) was defined as the percentage of participants with best (confirmed) overall response (BOR) of either complete response (CR) or partial response (PR) from start of study treatment until progressive disease (PD)/recurrence or death, as assessed by the investigator according to RECIST version 1.1. CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference baseline sum diameters; stable disease (SD): neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Participants needed to have two consecutive assessments of PR or CR at least 4 weeks apart to be a responder. Analysis of this outcome measure was only planned to occur at the time of primary analysis.

Time frame:
Median [full range] of follow-up time on study for Primary Analysis: 31.7 [0.0-44.3] months vs. 30.4 [0.0-45.8] months in Arm A vs. Arm B
Reported as:
Number · percentage of participants
Overall Response Rate (ORR)
percentage of participantsArm A: Pertuzumab + Trastuzumab + AI +/- ChemotherapyArm B: Trastuzumab + AI +/- Chemotherapy
ORR (CR + PR)63.3 (53.5 to 72.3)55.7 (45.7 to 65.3)
Non-responders (SD + PD + NE)36.7 (27.7 to 46.5)44.3 (34.7 to 54.3)
Complete Response (CR)7.3 (3.2 to 14.0)0.9 (0.0 to 5.1)
Partial Response (PR)56.0 (46.1 to 65.5)54.7 (44.8 to 64.4)
Stable Disease (SD)26.6 (18.6 to 35.9)27.4 (19.1 to 36.9)
Progressive Disease (PD)5.5 (2.0 to 11.6)12.3 (6.7 to 20.1)
Not Evaluable (NE)4.5 (1.5 to 10.4)4.7 (1.5 to 10.7)
Statistical analysis
  • Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy vs Arm B: Trastuzumab + AI +/- Chemotherapy · Chi-squared · p = 0.2537 (Test was performed at 2-sided alpha of 5%. There was no multiplicity adjustment.) · Difference in orr: 7.6 · 95% CI -6.0 to 21.3
SecondaryClinical Benefit Rate (CBR)

Clinical Benefit Rate (CBR) was defined as the percentage of participants with best (confirmed) partial response (PR) or complete response (CR) or stable disease (SD) for at least 6 months. According to RECIST version 1.1, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters; SD: neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study. Analysis of this outcome measure was only planned to occur at the time of primary analysis.

Time frame:
Median [full range] of follow-up time on study for Primary Analysis: 31.7 [0.0-44.3] months vs. 30.4 [0.0-45.8] months in Arm A vs. Arm B
Reported as:
Number · percentage of participants
Clinical Benefit Rate (CBR)
percentage of participantsArm A: Pertuzumab + Trastuzumab + AI +/- ChemotherapyArm B: Trastuzumab + AI +/- Chemotherapy
CBR (CR + PR + SD for ≥6 Months)68.8 (59.2 to 77.3)67.0 (57.2 to 75.8)
Complete Response (CR)7.3 (3.2 to 14.0)0.9 (0.0 to 5.1)
Partial Response (PR)56.0 (46.1 to 65.5)54.7 (44.8 to 64.4)
Stable Disease (SD) for ≥6 Months5.5 (2.0 to 11.6)11.3 (6.0 to 18.9)
Statistical analysis
  • Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy vs Arm B: Trastuzumab + AI +/- Chemotherapy · Chi-squared · p = 0.7743 (Test was performed at 2-sided alpha of 5%. There was no multiplicity adjustment.) · Difference in cbr: 1.8 · 95% CI -11.2 to 14.8
SecondaryDuration of Response (DOR)

Duration of response (DOR) was defined as the period from the date of initial confirmed partial response (PR) or complete response (CR) until the date of progressive disease or death from any cause. According to RECIST version 1.1, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Participants with no documented progression after CR or PR were censored at the last date at which they were known to have had the CR or PR, respectively. The primary analysis of DOR was planned to be performed at the same time as for PFS (when a total of 165 PFS events had occurred), and the final analysis was planned after at least 60 months follow-up for all participants.

Time frame:
Median [full range] of follow-up time on study for: Primary Analysis: 31.7 [0.0-44.3] months vs. 30.4 [0.0-45.8] months in Arm A vs. Arm B; Final Analysis: 73.20 [0.03-88.34] months vs. 71.06 [0.03-88.97] months in Arm A vs. Arm B
Reported as:
Median · months
Duration of Response (DOR)
monthsArm A: Pertuzumab + Trastuzumab + AI +/- ChemotherapyArm B: Trastuzumab + AI +/- Chemotherapy
Primary Analysis27.10 (14.13 to NA)15.11 (12.09 to 20.96)
Final Analysis27.40 (15.24 to 44.35)16.36 (12.09 to 20.96)
Statistical analysis
  • Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy vs Arm B: Trastuzumab + AI +/- Chemotherapy · Log Rank · p = 0.0181 (Test was performed at 2-sided alpha of 5%.) · Hazard ratio (hr): 0.57 · 95% CI 0.36 to 0.91Hazard ratio from stratified Cox proportional hazards model including stratification factors of induction chemotherapy and prior adjuvant hormone therapy.
  • Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy vs Arm B: Trastuzumab + AI +/- Chemotherapy · Log Rank · p = 0.0205 · Hazard ratio (hr): 0.62 · 95% CI 0.41 to 0.93Hazard ratio from stratified Cox proportional hazards model including stratification factors of induction chemotherapy and prior adjuvant hormone therapy.
SecondaryTime to Response (TTR)

Time to Response (TTR) was defined as the time from the date of randomization to the date of first complete response (CR) or partial response (PR). According to RECIST version 1.1, CR: disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm; PR: at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. For participants who did not have a confirmed response, a censored TTR was calculated at the date of the last adequate tumor assessment. If no tumor assessment is performed for the participant (or all post-baseline assessments are not evaluable or PD) the censoring day would be set to day 1 (date of randomization). Analysis of this outcome measure was only planned to occur at the time of primary analysis.

Time frame:
Median [full range] of follow-up time on study for Primary Analysis: 31.7 [0.0-44.3] months vs. 30.4 [0.0-45.8] months in Arm A vs. Arm B
Reported as:
Median · months
Time to Response (TTR)
monthsArm A: Pertuzumab + Trastuzumab + AI +/- ChemotherapyArm B: Trastuzumab + AI +/- Chemotherapy
Time to Response (TTR)2.53 (2.10 to 4.37)3.91 (2.10 to 4.17)
Statistical analysis
  • Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy vs Arm B: Trastuzumab + AI +/- Chemotherapy · Log Rank · p = 0.5597 (Test was performed at 2-sided alpha of 5%.) · Hazard ratio (hr): 1.11 · 95% CI 0.78 to 1.57Hazard ratio from stratified Cox proportional hazards model including the induction chemotherapy and prior adjuvant hormone therapy stratification factors.
SecondaryChange From Baseline in Health-Related Quality of Life as Determined by European Quality of Life 5-Dimension (EQ-5D) Visual Analog Scale (VAS) Scores

The EQ-5D VAS is a participant-rated questionnaire to assess health-related quality of life (QoL) in terms of a single index value. The VAS component rates current health state on a scale from 0 mm (worst imaginable health state) to 100 mm (best imaginable health state); higher scores indicate a better health state.

Time frame:
Baseline and every 3 cycles until treatment discontinuation (up to Cycle 120; 1 cycle is 21 days)
Reported as:
Mean · unit on a scale
Change From Baseline in Health-Related Quality of Life as Determined by European Quality of Life 5-Dimension (EQ-5D) Visual Analog Scale (VAS) Scores
unit on a scaleArm A: Pertuzumab + Trastuzumab + AI +/- ChemotherapyArm B: Trastuzumab + AI +/- Chemotherapy
Baseline (BL) - Value at Visit73.0 ± 19.3472.8 ± 18.83
Change from BL at Cycle 33.3 ± 14.901.9 ± 15.67
Change from BL at Cycle 63.5 ± 18.910.5 ± 13.63
Change from BL at Cycle 95.3 ± 18.802.1 ± 15.20
Change from BL at Cycle 1210.7 ± 17.914.0 ± 15.34
Change from BL at Cycle 159.1 ± 17.251.4 ± 22.16
Change from BL at Cycle 187.5 ± 12.853.5 ± 15.76
Change from BL at Cycle 215.8 ± 13.683.5 ± 19.70
Change from BL at Cycle 246.2 ± 14.303.2 ± 16.66
Change from BL at Cycle 277.5 ± 14.013.9 ± 22.00
Change from BL at Cycle 308.3 ± 14.254.9 ± 16.98
Change from BL at Cycle 335.1 ± 14.704.3 ± 15.59
Change from BL at Cycle 367.3 ± 15.195.9 ± 15.13
Change from BL at Cycle 398.1 ± 16.332.4 ± 29.68
Change from BL at Cycle 426.4 ± 19.189.0 ± 17.55
Change from BL at Cycle 459.7 ± 15.019.9 ± 19.52
Change from BL at Cycle 488.8 ± 12.506.8 ± 17.22
Change from BL at Cycle 517.2 ± 14.819.1 ± 19.11
Change from BL at Cycle 544.7 ± 23.487.6 ± 17.85
Change from BL at Cycle 576.8 ± 18.0810.5 ± 16.81
Change from BL at Cycle 608.2 ± 15.8810.9 ± 18.27
Change from BL at Cycle 634.0 ± 20.888.8 ± 14.64
Change from BL at Cycle 6610.4 ± 16.924.1 ± 15.69
Change from BL at Cycle 697.5 ± 17.355.0 ± 16.77
Change from BL at Cycle 726.2 ± 16.105.8 ± 16.10
Change from BL at Cycle 758.6 ± 19.125.1 ± 15.50
Change from BL at Cycle 7812.8 ± 17.456.9 ± 14.58
Change from BL at Cycle 8111.5 ± 18.398.0 ± 14.76
Change from BL at Cycle 8411.2 ± 19.711.3 ± 18.13
Change from BL at Cycle 8711.2 ± 18.17-3.0 ± 11.22
Change from BL at Cycle 9010.9 ± 18.28-3.0 ± 12.36
Change from BL at Cycle 937.1 ± 15.436.6 ± 13.89
Change from BL at Cycle 967.5 ± 16.048.6 ± 12.64
Change from BL at Cycle 994.4 ± 17.225.6 ± 16.71
Change from BL at Cycle 1025.6 ± 16.3510.0 ± 17.32
Change from BL at Cycle 1054.4 ± 16.350.0 ± NA
Change from BL at Cycle 1084.0 ± 14.390.0 ± NA
Change from BL at Cycle 1113.3 ± 21.50—
Change from BL at Cycle 114-1.3 ± 17.97—
Change from BL at Cycle 117-5.0 ± NA—
Change from BL at Cycle 120-5.0 ± NA—
SecondaryOverview of the Number of Participants With Adverse Events, Severity Determined According to NCI-CTCAE Version 4.03

All adverse events (AEs) occurring during the study and until the post-treatment safety follow-up visit approximately 28 days after last study medication were recorded; thereafter, only study drug-related serious adverse events (SAEs) continued to be collected. The investigator graded all AEs for severity per the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE), Version 4.03; if not listed, the AE was assessed as follows: Grade 1 = mild; Grade 2 = moderate; Grade 3 = severe; Grade 4 = life-threatening/disabling; Grade 5 = death. The investigator determined whether an AE was related to study drug and independently assessed severity and seriousness of each AE. AEs suggestive of congestive heart failure (CHF) were identified by the SMQ (wide) "Cardiac Failure" with a status of "serious", which included the preferred terms cardiac failure, left ventricular dysfunction, and pulmonary oedema.

Time frame:
From Baseline until the end of post-treatment follow-up (up to 89 months)
Reported as:
Count of participants · Participants
Overview of the Number of Participants With Adverse Events, Severity Determined According to NCI-CTCAE Version 4.03
ParticipantsArm A: Pertuzumab + Trastuzumab + AI +/- ChemotherapyArm B: Trastuzumab + AI +/- Chemotherapy
Any Adverse Event (AE)122122
Any AE, Grade ≥37251
Any Serious Adverse Event (SAE), Grade ≥33522
Any AE, Grade 511
Any SAE4628
SAE Related to Pertuzumab10NA
SAE Related to Trastuzumab92
SAE Related to Docetaxel64
SAE Related to Paclitaxel30
Any AE Leading to Discontinuation of Any Treatment2010
Any AE Leading to Pertuzumab Discontinuation16NA
Any AE Leading to Trastuzumab Discontinuation166
Any AE Leading to Interruption of Any Treatment5926
Any AE Leading to Pertuzumab Interruption44NA
Any AE Leading to Trastuzumab Interruption4816
Any AE Related to Pertuzumab82NA
Any AE Related to Trastuzumab8162
AE Suggestive of Congestive Heart Failure51
SecondaryNumber of Participants Who Died Over the Course of the Study by Reported Cause of Death and Time of Death Relative to First or Last Dose of Study Treatment

The causes of death over the course of the study, regardless of whether the death was related to study treatment, are listed by preferred term according to the Medical Dictionary for Regulatory Activities (MedDRA), version 22.1.

Time frame:
From Baseline until the end of post-treatment follow-up (up to 89 months)
Reported as:
Count of participants · Participants
Number of Participants Who Died Over the Course of the Study by Reported Cause of Death and Time of Death Relative to First or Last Dose of Study Treatment
ParticipantsArm A: Pertuzumab + Trastuzumab + AI +/- ChemotherapyArm B: Trastuzumab + AI +/- Chemotherapy
Total Number of Deaths6257
Deaths Related to Any Study Treatment00
Cause of Death: Cardiac Arrest10
Cause of Death: Craniocerebral Injury10
Cause of Death: Dyspnoea10
Cause of Death: High-grade B-cell Lymphoma10
Cause of Death: Sudden Death01
Cause of Death: Unevaluable Event21
Cause of Death: Progressive Disease5655
Total Deaths Within 30 Days After First Dose00
Total Deaths Within 28 Days After Last Dose12
Total Deaths Within 60 Days After Last Dose24
SecondaryChange From Baseline in Left Ventricular Ejection Fraction (LVEF) Values Over the Course of the Study

Left ventricular ejection fraction (LVEF) is the measurement of how much blood is being pumped out of the left ventricle of the heart (the main pumping chamber) with each contraction. A normal LVEF ranges from 55% to 70%, as measured by echocardiogram or multiple-gated acquisition (MUGA) scan. All participants must have had a baseline LVEF of at least (≥)50% to enroll in the study; patients with clinically significant cardiovascular disease or baseline LVEF below 50% were not eligible for this study.

Time frame:
Baseline and every 3 cycles until treatment discontinuation (up to Cycle 120; 1 cycle is 21 days)
Reported as:
Mean · Percentage points of LVEF
Change From Baseline in Left Ventricular Ejection Fraction (LVEF) Values Over the Course of the Study
Percentage points of LVEFArm A: Pertuzumab + Trastuzumab + AI +/- ChemotherapyArm B: Trastuzumab + AI +/- Chemotherapy
Baseline (BL) - Absolute LVEF at Visit63.8 ± 6.2363.9 ± 6.12
Change from BL at Cycle 3-1.0 ± 6.25-1.4 ± 6.23
Change from BL at Cycle 6-2.3 ± 6.66-1.3 ± 6.03
Change from BL at Cycle 9-2.5 ± 6.80-2.2 ± 6.52
Change from BL at Cycle 12-2.4 ± 8.05-2.8 ± 6.99
Change from BL at Cycle 15-2.9 ± 8.67-2.5 ± 6.94
Change from BL at Cycle 18-1.9 ± 6.42-1.3 ± 6.19
Change from BL at Cycle 21-1.1 ± 6.01-1.1 ± 6.64
Change from BL at Cycle 24-2.1 ± 6.82-0.6 ± 6.19
Change from BL at Cycle 27-1.6 ± 5.05-1.3 ± 5.87
Change from BL at Cycle 30-1.4 ± 5.20-0.3 ± 6.03
Change from BL at Cycle 33-2.8 ± 5.601.2 ± 6.71
Change from BL at Cycle 36-2.5 ± 5.50-0.2 ± 5.41
Change from BL at Cycle 39-2.6 ± 5.721.4 ± 4.87
Change from BL at Cycle 42-2.1 ± 5.911.9 ± 6.12
Change from BL at Cycle 45-1.0 ± 5.543.0 ± 5.27
Change from BL at Cycle 48-3.3 ± 6.56-0.2 ± 7.50
Change from BL at Cycle 51-1.4 ± 5.821.0 ± 4.19
Change from BL at Cycle 54-1.3 ± 6.17-1.0 ± 6.23
Change from BL at Cycle 57-1.7 ± 6.430.8 ± 5.68
Change from BL at Cycle 60-2.5 ± 5.54-0.9 ± 3.91
Change from BL at Cycle 63-2.1 ± 6.100.8 ± 5.99
Change from BL at Cycle 66-2.9 ± 7.80-0.4 ± 5.17
Change from BL at Cycle 69-2.1 ± 7.23-1.5 ± 7.68
Change from BL at Cycle 72-3.0 ± 4.97-1.0 ± 5.75
Change from BL at Cycle 75-3.3 ± 6.59-1.1 ± 6.97
Change from BL at Cycle 78-3.3 ± 5.58-1.1 ± 7.82
Change from BL at Cycle 81-2.9 ± 6.83-2.6 ± 6.00
Change from BL at Cycle 84-2.5 ± 7.66-4.5 ± 3.59
Change from BL at Cycle 87-3.8 ± 5.76-1.4 ± 5.12
Change from BL at Cycle 90-2.4 ± 7.690.4 ± 6.77
Change from BL at Cycle 93-1.8 ± 6.57-3.9 ± 6.00
Change from BL at Cycle 96-0.7 ± 7.45-3.2 ± 5.50
Change from BL at Cycle 99-3.4 ± 5.78-2.8 ± 8.41
Change from BL at Cycle 102-1.3 ± 6.12-1.6 ± 9.68
Change from BL at Cycle 105-0.4 ± 7.05-2.0 ± 12.17
Change from BL at Cycle 108-3.4 ± 5.32-3.3 ± 8.33
Change from BL at Cycle 111-6.3 ± 5.91-5.5 ± NA
Change from BL at Cycle 114-4.0 ± 5.35-1.4 ± NA
Change from BL at Cycle 117-11.0 ± NA—
Change from BL at Cycle 120-11.0 ± NA—

Adverse events

Collected over From Baseline until end of post-treatment follow-up (up to 89 months). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Arm A: Pertuzumab + Trastuzumab + AI +/- Chemotherapy63/129 (48.8%)46/127 (36.2%)120/127 (94.5%)
Arm B: Trastuzumab + AI +/- Chemotherapy57/129 (44.2%)28/124 (22.6%)116/124 (93.5%)
Most frequent serious events
Showing 10 of 72
Most frequent serious events
EventArm A: Pertuzumab + Trastuzumab + AI +/- ChemotherapyArm B: Trastuzumab + AI +/- Chemotherapy
PneumoniaInfections and infestations6/1271/124
Febrile neutropeniaBlood and lymphatic system disorders4/1272/124
Left ventricular dysfunctionCardiac disorders4/1270/124
HypersensitivityImmune system disorders3/1270/124
GastroenteritisInfections and infestations3/1270/124
Device related infectionInfections and infestations0/1272/124
Atrial fibrillationCardiac disorders2/1270/124
DiarrhoeaGastrointestinal disorders2/1271/124
VomitingGastrointestinal disorders2/1271/124
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/1270/124
Most frequent other events
Showing 10 of 58
Most frequent other events
EventArm A: Pertuzumab + Trastuzumab + AI +/- ChemotherapyArm B: Trastuzumab + AI +/- Chemotherapy
DiarrhoeaGastrointestinal disorders70/12745/124
NauseaGastrointestinal disorders47/12734/124
AlopeciaSkin and subcutaneous tissue disorders38/12740/124
AstheniaGeneral disorders39/12732/124
ArthralgiaMusculoskeletal and connective tissue disorders38/12731/124
Oedema peripheralGeneral disorders34/12723/124
VomitingGastrointestinal disorders31/12721/124
AnaemiaBlood and lymphatic system disorders28/12718/124
FatigueGeneral disorders21/12725/124
CoughRespiratory, thoracic and mediastinal disorders25/12718/124

Baseline characteristics

Intent-to-Treat (ITT) population included all randomized participants.

Age, Continuous
Age, Continuous(Years)Arm A: Pertuzumab + Trastuzumab + AI +/- ChemotherapyArm B: Trastuzumab + AI +/- ChemotherapyTotal
Mean60.9 ± 10.8562.3 ± 11.5461.6 ± 11.20
Sex: Female, Male
Sex: Female, Male(Participants)Arm A: Pertuzumab + Trastuzumab + AI +/- ChemotherapyArm B: Trastuzumab + AI +/- ChemotherapyTotal
Female129129258
Male000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Arm A: Pertuzumab + Trastuzumab + AI +/- ChemotherapyArm B: Trastuzumab + AI +/- ChemotherapyTotal
American Indian or Alaska Native011
Asian101828
Native Hawaiian or Other Pacific Islander000
Black or African American459
White10493197
More than one race000
Unknown or Not Reported111223
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Arm A: Pertuzumab + Trastuzumab + AI +/- ChemotherapyArm B: Trastuzumab + AI +/- ChemotherapyTotal
Hispanic/Latino454085
Chinese000
Indian (Indian subcontinent)101626
Japanese011
Mixed Ethnicity000
Other6360123
Missing111223
Number of Participants by Induction Chemotherapy and Prior Adjuvant Hormone Therapy
Number of Participants by Induction Chemotherapy and Prior Adjuvant Hormone Therapy(Participants)Arm A: Pertuzumab + Trastuzumab + AI +/- ChemotherapyArm B: Trastuzumab + AI +/- ChemotherapyTotal
Induction Chemotherapy - Yes — <12 Months Since Hormone Therapy121224
Induction Chemotherapy - Yes — ≥12 Months Since Hormone Therapy242347
Induction Chemotherapy - Yes — No Prior Hormone Therapy393877
Induction Chemotherapy - No — <12 Months Since Hormone Therapy121224
Induction Chemotherapy - No — ≥12 Months Since Hormone Therapy181937
Induction Chemotherapy - No — No Prior Hormone Therapy242549
08

Study locations

82 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35249, United States
  • Ironwood Cancer TX & Rsch Ctrs
    Chandler, Arizona 85224, United States
  • Genesis Cancer Center
    Hot Springs, Arkansas 71913, United States
  • Comprehensive Blood & CA Ctr; Research
    Bakersfield, California 93309, United States
  • Rocky Mountain Cancer Center - Denver
    Denver, Colorado 80220, United States
  • Norwalk Hospital
    Norwalk, Connecticut 06856, United States
  • Advanced Medical Specialties
    Miami, Florida 33176, United States
  • Georgia Cancer Specialists - Northside
    Atlanta, Georgia 30341, United States
  • Northwest Georgia Oncology Centers, a Service of WellStar Cobb Hospital
    Marietta, Georgia 30060, United States
  • Cancer Center of Kansas
    Wichita, Kansas 67214-3728, United States
  • Crescent City Rsrch Cnsrtm, LLC
    Marrero, Louisiana 70072, United States
  • Weinberg CA Inst Franklin Sq
    Baltimore, Maryland 21237, United States
  • Center For Cancer and Blood Disorders
    Bethesda, Maryland 20817, United States
  • Washington University School of Medicine; Internal Medicine - Renal
    Saint Louis, Missouri 63110, United States
  • Hematology Oncology Associates; Carol G. Simon Ctr
    Morristown, New Jersey 07960, United States
  • Cooper Hospital; Hematology & Oncology
    Voorhees, New Jersey 08043, United States
  • NS-Long Island Jewish Hlth Sys
    Lake Success, New York 11042, United States
  • ProHEALTH Care Associates LLP
    Lake Success, New York 11042, United States
  • UPMC Cancer Centers
    Pittsburgh, Pennsylvania 15232, United States
  • Baylor College of Medicine; Lester & Sue Smith Breast Ctr
    Houston, Texas 77030, United States
  • Scott and White Hospital; Cancer Center
    Temple, Texas 76508, United States
  • Instituto do Cancer do Estado de Sao Paulo - ICESP
    Sao Paulo, SP 01246-000, Brazil
  • Hospital Perola Byington
    Sao Paulo, SP 01317-904, Brazil
  • Inst. Brasileiro de Controle Ao Cancer; Oncologia Clinica / Quimioterapia
    Sao Paulo, SP 03102-002, Brazil
  • Hospital Sao Jose
    São Paulo, SP CEP 01321-001, Brazil
  • HOPITAL JEAN MINJOZ; Oncologie
    Besancon, 25030, France
  • Clinique Tivoli; Sce Radiotherapie
    Bordeaux, 33000, France
  • Hopital Morvan; Oncologie - Radiotherapie
    Brest, 29609, France
  • Centre Jean Perrin; Oncologie
    Clermont Ferrand, 63011, France
  • Clinique De La Sauvegarde; Chimiotherapie
    Lyon, 69337, France
  • Centre Catherine de Sienne; Chimiotherapie
    Nantes, 44202, France
  • Centre Antoine Lacassagne; Hopital De Jour A2
    Nice, 06189, France
  • CH De Senlis; Medecine 2
    Senlis, 60309, France
  • Clinique Pasteur; Oncologie Medicale
    Toulouse, 31076, France
  • Centre Alexis Vautrin; Oncologie Medicale
    Vandoeuvre-les-nancy, 54519, France
  • Indraprastha Apollo Hospitals
    New Delhi, Delhi 110076, India
  • Bangalore Institute of Oncology
    Bangalore, Karnataka 560027, India
  • Jaslok Hospital & Research Centre; Medical Oncology
    Mumbai, Maharashtra 400026, India
  • Apollo Speciality Hospital
    Chennai, 600035, India
  • Ruby Hall Clinic
    Pune, 411 001, India
  • Istituto Nazionale Tumori Fondazione G. Pascale
    Napoli, Campania 80131, Italy
  • Università degli Studi Federico II; Clinica di Oncologia Medica
    Napoli, Campania 80131, Italy
  • Azienda Ospedaliero-Universitaria S.Orsola-Malpighi; Unità Operativa Oncologia Medica
    Bologna, Emilia-Romagna 40138, Italy
  • Ospedale Regionale Di Parma; Divisione Di Oncologia Medica
    Parma, Emilia-Romagna 43100, Italy
  • A.O. Santa Maria Degli Angeli; U.O Di Oncologia Medica
    Pordenone, Friuli-Venezia Giulia 33170, Italy
  • Ospedale S.S. Trinità Nuovo; Divisione Oncologia
    Sora, Lazio 03039, Italy
  • Casa di Cura MultiMedica Ospedale di Castellanza; UO Senologia Medica
    Castellanza, Lombardia 21053, Italy
  • Irccs Istituto Nazionale Dei Tumori (Int);S.C. Medicina Oncologica 1
    Milano, Lombardia 20133, Italy
  • IRCCS Fondazione Maugeri; Oncologia Medica I
    Pavia, Lombardia 27100, Italy
  • Irccs Ist. Tumori Giovanni Paolo Ii; Dipartimento Oncologia Medica
    Bari, Puglia 70124, Italy
  • Ospedale Antonio Perrino; Oncologia Medica
    Brindisi, Puglia 72100, Italy
  • Ospedale Vito Fazzi; Div. Oncoematologia
    Lecce, Puglia 73100, Italy
  • Az Ospedaliera Nuovo Garibaldi Quartiere Nesima; Oncologia Medica
    Catania, Sicilia 95122, Italy
  • A.O. Careggi; Radioterapia
    Firenze, Toscana 50139, Italy
  • Ospedale Misericordia E Dolce; Oncologia Medica
    Prato, Toscana 59100, Italy
  • Hospital Universitari Germans Trias i Pujol; Servicio de Oncologia
    Badalona, Barcelona 08916, Spain
  • Hospital Provincial de Castellon; Servicio de Oncologia
    Castellon de La Plana, Castellon 12002, Spain
  • Hospital Universitario Reina Sofia; Servicio de Oncologia
    Córdoba, Cordoba 14004, Spain
  • IInstituto Oncologico de San Sebastian, Oncologikoa; Servicio de Oncologia
    San Sebastian, Guipuzcoa 20014, Spain
  • Hospital de Donostia; Servicio de Oncologia Medica
    San Sebastian, Guipuzcoa 20080, Spain
  • Hospital del Mar; Servicio de Oncologia
    Barcelona, 08003, Spain
  • Hospital de San Pedro de Alcantara
    Caceres, 10003, Spain
  • Complejo Hospitalario Universitario A Coruña (CHUAC, Materno Infantil), Oncología
    La Coruña, 15006, Spain
  • Centro Oncológico Gallego José Antonio Quiroga y Piñeiro, Servicio de Oncologia
    La Coruña, 15009, Spain
  • Hospital Universitari Arnau de Vilanova de Lleida; Servicio de Oncologia
    Lerida, 25198, Spain
  • Hospital Ramon y Cajal; Servicio de Oncologia
    Madrid, 28034, Spain
  • Hospital Universitario Clínico San Carlos; Servicio de Oncologia
    Madrid, 28040, Spain
  • Hospital Universitario Virgen de Arrixaca; Servicio de Oncologia
    Murcia, 30120, Spain
  • Hospital Universitario Virgen Macarena; Servicio de Oncologia
    Sevilla, 41009, Spain
  • Hospital Clinico Universitario de Valencia; Servicio de Onco-hematologia
    Valencia, 46010, Spain
  • Hospital Universitario Miguel Servet; Servicio Oncologia
    Zaragoza, 50009, Spain
  • Hacettepe Uni Medical Faculty Hospital; Oncology Dept
    Ankara, 06100, Turkey
  • Ankara City Hospital
    Ankara, 06490, Turkey
  • Ege Uni Medical Faculty Hospital; Oncology Dept
    Izmir, 35100, Turkey
  • Inonu University Medical Faculty Turgut Ozal Medical Center Medical Oncology Department
    Malatya, 44280, Turkey
  • Brighton and Sussex Univ Hosp
    Brighton, BN2 5BE, United Kingdom
  • University Hospital coventry; Oncology Department
    Coventry, CV2 2DX, United Kingdom
  • Beatson West of Scotland Cancer Centre
    Glasgow, G12 0YN, United Kingdom
  • Queen Elizabeth Hospital
    London, SE18 4QH, United Kingdom
  • Queen Alexandra Hospital, Portsmouth
    Portsmouth, PO6 3LY, United Kingdom
  • Scarborough General Hospital
    Scarborough, YO12 6QL, United Kingdom
  • Weston Park Hospital; Cancer Clinical Trials Centre
    Sheffield, S10 2SJ, United Kingdom
09

References and documents

Publications

  • Rimawi M, Ferrero JM, de la Haba-Rodriguez J, Poole C, De Placido S, Osborne CK, Hegg R, Easton V, Wohlfarth C, Arpino G; PERTAIN Study Group. First-Line Trastuzumab Plus an Aromatase Inhibitor, With or Without Pertuzumab, in Human Epidermal Growth Factor Receptor 2-Positive and Hormone Receptor-Positive Metastatic or Locally Advanced Breast Cancer (PERTAIN): A Randomized, Open-Label Phase II Trial. J Clin Oncol. 2018 Oct 1;36(28):2826-2835. doi: 10.1200/JCO.2017.76.7863. Epub 2018 Aug 14. PubMed 30106636 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2012 to primary completion in Mar 2016, 49 months.

Results were first posted in Jun 2017, 1 year 2 months after primary completion.

Of 232 industry-sponsored phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 53. This study's 49 months is above that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 82.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 6, 2011
First posted
Dec 14, 2011
StartActual
Feb 17, 2012
Primary completionActual
Mar 17, 2016
CompletionActual
Nov 14, 2019
Results first posted
Jun 7, 2017
Last update
Oct 28, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 28, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01491737
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Dec 14, 2011
Start date
Feb 17, 2012
Primary completion
Mar 17, 2016
Completion
Nov 14, 2019
Results posted
Jun 7, 2017
Last update
Oct 28, 2020

Study contacts

Clinical Trials
study director · Hoffmann-La Roche

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pertuzumab

Start the discussion